e-learning
resources
Vienna 2009
Monday, 14.09.2009
Treatment of airways disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Human alpha-1 proteinase inhibitor (tal6004) manufacturing process and pathogen safety
N. Roth, G. Buczynski, K. Cai, W. Osheroff, M. Burdick, J. Wang, H. Renfrow, M. Nelson, J. Hotta (Research Triangle Park, United States Of America)
Source:
Annual Congress 2009 - Treatment of airways disease
Session:
Treatment of airways disease
Session type:
Thematic Poster Session
Number:
2076
Disease area:
Airway diseases, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. Roth, G. Buczynski, K. Cai, W. Osheroff, M. Burdick, J. Wang, H. Renfrow, M. Nelson, J. Hotta (Research Triangle Park, United States Of America). Human alpha-1 proteinase inhibitor (tal6004) manufacturing process and pathogen safety. Eur Respir J 2009; 34: Suppl. 53, 2076
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Alpha-1 antitrypsin genotypes and associated inhibitory activity towards neutrophil serine proteinases, in vitro
Source: International Congress 2015 – Promising novel findings in translational pulmonary research
Year: 2015
LSC Abstract – A functional variant of secretory leukocyte protease inhibitor (SLPI) with improved anti-inflammatory activity against pulmonary infection
Source: International Congress 2015 – Immunomodulation: basic science and clinical aspects
Year: 2015
Alpha-1 antitrypsin genotypes and associated inhibitory activity towards neutrophil serine proteinases, in vivo
Source: International Congress 2015 – Translational research in respiratory care: new findings
Year: 2015
Single and repeated dose inhalation toxicology studies with alpha-1 proteinase inhibitor TAL6005
Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD
Year: 2008
Safety, immunogenicity and pharmacokinetics (PK) of a 120 mg/kg/week dose of alpha
1
-proteinase inhibitor in alpha
1
-antitrypsin deficiency
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013
A functional variant of secretory leukocyte protease inhibitor (SLPI) with improved anti-inflammatory activity against pulmonary infection
Source: Lung Science Conference 2015
Year: 2015
Nonclinical safety profiles of DS-1515, a novel oral PI3Kd inhibitor.
Source: International Congress 2018 – Basic pharmacology
Year: 2018
Safety and pharmacology of a soluble epoxide hydrolase inhibitor
Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD
Year: 2015
Increased proportion of slow decliners in patients with alpha-1 protease inhibitor (A1-PI) deficiency following treatment with A1-PI
Source: International Congress 2016 – New and old therapies for chronic lung diseases
Year: 2016
In-vitro evaluation of a new potent, selective pan-Janus kinase (JAK) inhibitor VR588
Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD
Year: 2015
Chronic inhalation toxicity study of nebulized alpha
1
proteinase inhibitor (alpha
1
-PI), TAL6005, in rodents
Source: Annual Congress 2010 - Models of airways disease
Year: 2010
Human airway trypsin-like protease stimulates protease activated receptors and interactions of these receptors
Source: International Congress 2019 – Immunopathological mechanisms of lung disease
Year: 2019
Plant proteinase from
bauhinia bauhinioides
kallikrein inhibitor (BbKI) attenuates inflammation and remodelling induced by elastase in mice
Source: Annual Congress 2013 –Novel mechanisms in lung injury
Year: 2013
Plant proteinase inhibitor from
crataeva tapia (CrataBl)
attenuates inflammation and remodelling induced by elastase in mice
Source: Annual Congress 2013 –Novel mechanisms in lung injury
Year: 2013
Development of secretory leukocyte protease inhibitor (SLPI) variants resistant to degradation by neutrophil elastase
Source: International Congress 2014 – New studies into pulmonary proteases and antiproteases
Year: 2014
AZD9668: Pharmacological characterisation of a novel oral inhibitor of neutrophil elastase (NE)
Source: Annual Congress 2010 - Pre-clinical models of airways disease
Year: 2010
Target engagement confirmed in man with a dipeptidyl peptidase 1 inhibitor
Source: International Congress 2017 – Management of COPD
Year: 2017
Dipeptidyl peptidase I (DPPI) cleaves surfactant protein D (SP-D): A mechanism for immune compromise in the lung
Source: International Congress 2016 – Molecular immunology of the lung
Year: 2016
Plant proteinase from Bauhinia bauhinioides Kallikrein inhibitor (BbKI) attenuates mechanics, inflammation and remodelling induced by elastase in mice
Source: Annual Congress 2012 - The many roads to lung injury
Year: 2012
Increased detection of interleukin-;5 in sputum by addition of protease inhibitors
Source: Eur Respir J 2001; 18: 685-691
Year: 2001
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept